As most countries in the coming weeks brace their healthcare systems for the pandemic peak, many in the private sector […]
With a third of the global population under some form of lockdown restriction, it’s hard to imagine ever returning to […]
Likely no one needs any reminder that the current pandemic will have huge effect our economy for many years to […]
In a previous post, we have hinted that we are working hard behind the scenes to further support genomic start […]
FLG: Could you give us an introduction of yourself and the work you do? I’m Sandra Smieszek and I’m the […]
The delta COVID-19 variant has contributed to a surge in the number of COVID cases across the globe, including a […]
Proteolysis-targeting chimeras (PROTACs) are an emerging class of drugs that may offer new opportunities to overcome limitations associated with small-molecule […]
A recent study aimed to assess the safety of intravitreal ranibizumab biosimilar molecule (Razumab) treatment for chorioretinal diseases under real-world […]
We summarise a recent article, published in BMJ, that explored why certain age bands used for children in paediatric studies […]
We recently interviewed Anandbir Brar, Chief Executive Officer of Excelra. Excelra is the lead sponsor for our D4 Global virtual event. […]
